This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Approves Avastin To Treat Brain Cancer

SOUTH SAN FRANCISCO, Calif. (AP) ¿ The Food and Drug Administration granted accelerated approval to Roche's cancer drug Avastin as a treatment for glioblastoma, a type of brain cancer, Genentech Inc. said Wednesday.

Avastin was developed by Genentech and sold through a partnership with Roche. Switzerland-based Roche agreed to buy Genentech in March.

The FDA sped up its review process because it has been more than 10 years since a new treatment for glioblastoma was approved, according to Genentech. The approval is based on the drug's ability to achieve a partial or complete response in clinical trials. Genentech said there is currently no data showing the drug reduces symptoms or improves survival.

The company is also planning a late stage trial of Avastin as a treatment for newly diagnosed glioblastoma. The company said about 10,000 people in the U.S. have glioblastoma, and tumors usually come back after initial treatment.

Avastin is approved a treatment for various forms of colon, breast and lung cancers. Last month, the company said the drug failed to stop early stage colon cancer.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%
YHOO $44.52 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs